Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06855498 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

Study acronym: STOP-LTR
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 57 record versions are listed below. See every version on ClinicalTrials.gov ↗

  1. Study sites: 297 to 296
  2. Trial sites reduced: 318 → 297 locations
  3. Study sites revised (318)v55 See this version in full on ClinicalTrials.gov ↗
  4. Study sites revised (318)v54 See this version in full on ClinicalTrials.gov ↗
  5. Study sites: 316 to 318v53
Show 7 earlier versionsHide 7 earlier versions
  1. Study sites revised (316)v52 See this version in full on ClinicalTrials.gov ↗
  2. Study sites: 317 to 316v51
  3. Site details revised at 6 of 317 sitesv50
  4. Study sites: 319 to 317v49
  5. Study sites: 318 to 319v48
  6. Study sites revised (318)v47 See this version in full on ClinicalTrials.gov ↗
  7. Study sites: 316 to 318v46
  1. Trial sites reduced: 327 → 316 locations Trial sites reduced: 330 → 327 locationsv45 Show 1 more changeShow less
    • Trial sites reduced: 330 → 327 locations
  2. Study sites: 330 to 327v44
  3. Study sites: 327 to 330v43
  4. Site details revised at 5 of 327 sitesv42
  5. Study sites: 329 to 327v41
  6. Site details revised at 4 of 329 sitesv40
  7. Study sites: 332 to 329v39
  8. Study sites revised (332)v38 See this version in full on ClinicalTrials.gov ↗
  9. Site details revised at 3 of 332 sitesv37
  10. Study sites: 331 to 332v36
  11. Study sites: 336 to 331v35
  12. Study sites: 338 to 336v34
  13. Study sites: 339 to 338v33
  14. Study sites: 341 to 339v32
  15. Study sites: 342 to 341v31
  16. Study sites revised (342)v30 See this version in full on ClinicalTrials.gov ↗
  17. Study sites revised (342)v29 See this version in full on ClinicalTrials.gov ↗
  18. Study sites: 344 to 342v28
  19. Study sites: 343 to 344v27
  20. Site details revised at 4 of 343 sitesv26
  21. Site details revised at 1 of 343 sitesv25
  22. Site details revised at 2 of 343 sitesv24
  23. Site details revised at 1 of 343 sitesv23
  24. Site details revised at 2 of 343 sitesv22
  25. Study sites: 344 to 343v21
  26. Study sites: 343 to 344v20
  27. Study sites: 342 to 343v19
  28. Site details revised at 1 of 342 sitesv18
  29. Study sites: 341 to 342v17
  30. Study sites: 319 to 341v16
  31. Study sites: 318 to 319v15
  32. Re-verified, no change to tracked fieldsv14
  33. Study sites revised (318)v13 See this version in full on ClinicalTrials.gov ↗
  34. Study sites: 319 to 318v12
  35. Study sites: 350 to 319v11
  36. Study sites: 349 to 350v10
  37. Study sites: 316 to 349v9
  38. Study sites: 309 to 316v8
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.
Trial Details
NCT Number NCT06855498
Lead Sponsor Incyte Corporation
Conditions Hidradenitis Suppurativa (HS)
Enrollment 600 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov